Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.70 |
| ▸ | TNF | P01375 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | ACHE | P22303 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23144749 | 1.00 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL27334771 | 1.00 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL27348729 | 1.00 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL266179 | 0.99 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Pentifylline SCHEMBL4779804 | 0.96 | ADORA2B (0.65) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL516018 | 0.94 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL16120981 | 0.94 | ADORA2B (0.77) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL8682905 | 0.94 | ADORA2B (0.62) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7994674 | 0.94 | ADORA2B (0.62) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL8149700 | 0.94 | ADORA2B (0.62) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1615 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| CN-119258134-A | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating cough variant asthma | 江苏康缘药业股份有限公司 | 2025-01-07 | — | — | CN | claimed |
| US-20240261291-A1 | Ophthalmic Compositions and/or Methods for Presbyopia, Mydriasis and/or Ocular Discomfort Management | BRIEN HOLDEN VISION INSTITUTE LTD (AU) | 2024-08-08 | — | — | US | claimed |
| US-20240216292-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2024-07-04 | — | — | US | claimed |
| CN-117986146-A | Preparation method and detection method of citric acid pentovirine impurity | 河南优凯制药有限公司 | 2024-05-07 | — | — | CN | claimed |
| US-20240108588-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2024-04-04 | — | — | US | claimed |
| EP-4334436-A1 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | Yeda Research and Development Co. Ltd (IL) | 2024-03-13 | — | — | EP | claimed |
| EP-0165308-A4 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1986-05-16 | — | — | EP | claimed |
| EP-0069958-B1 | Method for the preparation of gastro compatible pharmaceutical forms of xanthine derivatives. | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-04-02 | — | — | EP | claimed |
| EP-0169466-A2 | Mixture of xanthin derivatives and O-acetyl-salicylic acid, or their pharmacologically acceptable salts, and its use | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-01-29 | — | — | EP | claimed |
| US-4567183-A | SYNERGISTIC, POTENTIATION | ANALGESIC ASSOCIATES (US) | 1986-01-28 | — | — | US | claimed |
| EP-0167566-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE, Abraham (US) | 1986-01-15 | — | — | EP | claimed |
| EP-0165308-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1985-12-27 | — | — | EP | claimed |
| US-4558051-A | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same | RICHARDSON-VICKS, INC. (US) | 1985-12-10 | — | — | US | claimed |
| US-4542011-A | PROTECTIVE COATINGS | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-09-17 | — | — | US | claimed |
| WO-1985002540-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | RICHARDSON-VICKS, INC. (US) | 1985-06-20 | — | — | WO | claimed |
| WO-1985002542-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE ABRAHAM | 1985-06-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | PDE4A 2235/4885PDE4B 2739/4885PDE4C 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.